| abstract |
Albuminuria or diabetic nephropathy in human type 2 diabetic patients with insufficient control of albuminuria despite treatment with angiotensin converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) Of novel pharmaceutical compositions for the treatment, prevention, reduction of risk, delay of onset or slowing of progression. A pharmaceutical composition comprising linagliptin, wherein linagliptin is administered to the patient at an oral dose of 5 mg per day, together with an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB). A pharmaceutical composition. [Selection figure] None |